Department of Cardiovascular Sciences, University of Leicester, National Institute for Health Research, Leicester Biomedical Research Centre, Leicester, United Kingdom; Department of Cardiology, Aintree University Hospital, Liverpool, United Kingdom.
Department of Cardiovascular Sciences, University of Leicester, National Institute for Health Research, Leicester Biomedical Research Centre, Leicester, United Kingdom; Department of Cardiology, Kettering General Hospital National Health Service Foundation Trust, Kettering, United Kingdom.
JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2291-2301. doi: 10.1016/j.jcmg.2018.11.031. Epub 2019 Feb 13.
OBJECTIVES: This study sought to assess the presence and extent of focal and diffuse fibrosis in heart failure in patients with preserved ejection fraction (HFpEF) compared to asymptomatic control subjects, and the relationship of fibrosis to clinical outcome. BACKGROUND: Myocardial fibrosis has been implicated in the pathophysiology of HFpEF. METHODS: In this prospective, observational study, 140 subjects of similar age and sex (HFpEF: n = 96; control subjects: n = 44; 73 ± 8 years of age; 49% males) underwent cardiac magnetic resonance imaging. Late gadolinium-enhanced (LGE) imaging and T1 mapping to calculate myocardial extracellular volume indexed to body surface area (iECV) were used to assess fibrosis. RESULTS: Patients with HFpEF had more concentric remodeling and worse diastolic function. Focal fibrosis was more frequent in HFpEF subjects (overall: n = 49; infarction: n = 17; nonischemic cases: n = 36; mixed patterns: n = 4) than in control subjects (overall: n = 3). Diffuse fibrosis was also greater in HFpEF subjects than control subjects (iECV: 13.7 ± 4.4 ml/m versus 10.9 ± 2.8 ml/m; p < 0.0001). During median follow-up (1,429 days), there were 42 composite events (14 deaths; 28 heart failure hospitalizations) in cases of HFpEF. Myocardial infarction revealed on LGE imaging was a predictor of outcomes on univariate analysis only. With multivariate analysis, iECV (hazard ratio [HR]: 1.689; 95% confidence interval [CI]: 1.141 to 2.501; p = 0.009) was an independent predictor of outcome along with mitral peak velocity of early filling (E)-to-early diastolic mitral annular velocity (E') (E/E') ratio (HR: 1.716; 95% CI: 1.191 to 2.472; p = 0.004) and prior HF hospitalization (HR: 2.537; 95% CI: 1.090 to 5.902; p = 0.031). iECV was also significantly associated with ventricular/left atrial remodeling and renal dysfunction: right ventricular end-diastolic volume indexed (r = 0.456; p < 0.0001), left ventricular mass/volume (r = 0.348; p = 0.001), maximal left atrial volume indexed (r = 0. 269; p = 0.009), and creatinine (r = 0.271; p = 0.009). CONCLUSIONS: Both focal and diffuse myocardial fibrosis are more prevalent in HFpEF subjects than in control subjects of similar age and sex. iECV significantly correlates with indices of ventricular/left atrial remodeling and renal dysfunction and is an independent predictor of adverse outcome in HFpEF. (Developing Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction [DIAMONDHFpEF]; NCT03050593).
目的:本研究旨在评估射血分数保留的心力衰竭(HFpEF)患者与无症状对照受试者之间局灶性和弥漫性纤维化的存在和程度,并探讨纤维化与临床结局的关系。
背景:心肌纤维化与 HFpEF 的病理生理学有关。
方法:在这项前瞻性观察性研究中,140 名年龄和性别相似的受试者(HFpEF:n=96;对照组:n=44;73±8 岁;49%为男性)接受了心脏磁共振成像检查。使用钆延迟增强(LGE)成像和 T1 映射来计算心肌细胞外容积指数(iECV),以评估纤维化。
结果:HFpEF 患者存在更严重的向心性重构和舒张功能障碍。HFpEF 患者中局灶性纤维化更为常见(总体:n=49;梗死:n=17;非缺血性病例:n=36;混合模式:n=4),而对照组中局灶性纤维化更为少见(总体:n=3)。HFpEF 患者的弥漫性纤维化也比对照组更严重(iECV:13.7±4.4ml/m 与 10.9±2.8ml/m;p<0.0001)。在中位随访期间(1429 天),HFpEF 患者中有 42 例复合事件(14 例死亡;28 例心力衰竭住院)。LGE 成像上显示的心肌梗死仅在单变量分析中是预后的预测因素。多变量分析显示,iECV(风险比[HR]:1.689;95%置信区间[CI]:1.141 至 2.501;p=0.009)和二尖瓣早期充盈峰速度(E)与早期舒张二尖瓣环速度(E')的比值(E/E')(HR:1.716;95%CI:1.191 至 2.472;p=0.004)以及既往心力衰竭住院史(HR:2.537;95%CI:1.090 至 5.902;p=0.031)是独立的预后预测因素。iECV 还与心室/左心房重构和肾功能障碍显著相关:右心室舒张末期容积指数(r=0.456;p<0.0001)、左心室质量/容积(r=0.348;p=0.001)、最大左心房容积指数(r=0.269;p=0.009)和肌酐(r=0.271;p=0.009)。
结论:与年龄和性别相似的对照组相比,HFpEF 患者中局灶性和弥漫性心肌纤维化更为常见。iECV 与心室/左心房重构和肾功能障碍指数显著相关,是 HFpEF 不良预后的独立预测因素。(描述射血分数保留心力衰竭的发展成像和血浆生物标志物 [DIAMONDHFpEF];NCT03050593)。
JACC Cardiovasc Imaging. 2019-2-13
JACC Cardiovasc Imaging. 2022-6
Int J Cardiovasc Imaging. 2021-1
Int J Cardiovasc Imaging. 2019-8-10
JACC Cardiovasc Imaging. 2016-12-21
PLoS One. 2025-8-29
Diagnostics (Basel). 2025-8-20
Circ Res. 2025-5-23
Front Cardiovasc Med. 2025-4-23
J Cardiovasc Magn Reson. 2025-2-17
Eur Heart J Imaging Methods Pract. 2024-12-26
Eur Heart J Cardiovasc Imaging. 2024-10-30